Leticia Sarasa

1.7k total citations · 1 hit paper
21 papers, 814 citations indexed

About

Leticia Sarasa is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Leticia Sarasa has authored 21 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Physiology, 11 papers in Psychiatry and Mental health and 5 papers in Molecular Biology. Recurrent topics in Leticia Sarasa's work include Alzheimer's disease research and treatments (21 papers), Dementia and Cognitive Impairment Research (11 papers) and Neuroinflammation and Neurodegeneration Mechanisms (4 papers). Leticia Sarasa is often cited by papers focused on Alzheimer's disease research and treatments (21 papers), Dementia and Cognitive Impairment Research (11 papers) and Neuroinflammation and Neurodegeneration Mechanisms (4 papers). Leticia Sarasa collaborates with scholars based in Spain, United Kingdom and United States. Leticia Sarasa's co-authors include José Antonio Allué, Pedro Pesini, Shorena Janelidze, Kaj Blennow, Henrik Zetterberg, Oskar Hansson, Charlotte E. Teunissen, Inge M.W. Verberk, Kenji Toba and Vitaliy Ovod and has published in prestigious journals such as Neuroscience, Neurobiology of Aging and Journal of Alzheimer s Disease.

In The Last Decade

Leticia Sarasa

20 papers receiving 797 citations

Hit Papers

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assay... 2021 2026 2022 2024 2021 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
    2021 267 citations Shorena Janelidze, Charlotte E. Teunissen et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leticia Sarasa Spain 10 603 446 179 165 66 21 814
Wagner S. Brum Brazil 16 700 1.2× 561 1.3× 209 1.2× 173 1.0× 38 0.6× 37 1.0k
Josef Pannee Sweden 15 627 1.0× 419 0.9× 306 1.7× 105 0.6× 51 0.8× 22 861
Jeroen Vanbrabant Belgium 10 603 1.0× 484 1.1× 184 1.0× 165 1.0× 41 0.6× 22 800
Virginia Pérez‐Grijalba Spain 14 541 0.9× 300 0.7× 261 1.5× 136 0.8× 126 1.9× 19 775
Marwan Sabbagh United States 8 432 0.7× 349 0.8× 218 1.2× 154 0.9× 69 1.0× 13 927
Federica Ribaldi Switzerland 14 384 0.6× 347 0.8× 163 0.9× 117 0.7× 46 0.7× 52 760
Manu Vandijck Belgium 11 660 1.1× 559 1.3× 189 1.1× 165 1.0× 37 0.6× 29 904
Joakim Hertze Sweden 10 661 1.1× 434 1.0× 235 1.3× 321 1.9× 51 0.8× 11 990
Francesco Garaci Italy 17 595 1.0× 278 0.6× 285 1.6× 162 1.0× 65 1.0× 25 1.1k
Luiza Spiru Romania 7 428 0.7× 427 1.0× 88 0.5× 135 0.8× 66 1.0× 26 688

Countries citing papers authored by Leticia Sarasa

Since Specialization
Citations

This map shows the geographic impact of Leticia Sarasa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leticia Sarasa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leticia Sarasa more than expected).

Fields of papers citing papers by Leticia Sarasa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leticia Sarasa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leticia Sarasa. The network helps show where Leticia Sarasa may publish in the future.

Co-authorship network of co-authors of Leticia Sarasa

This figure shows the co-authorship network connecting the top 25 collaborators of Leticia Sarasa. A scholar is included among the top collaborators of Leticia Sarasa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leticia Sarasa. Leticia Sarasa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Allué, José Antonio, Leticia Sarasa, Noelia Fandos, et al.. (2025). Clinical validation of a plasma-based antibody-free LC–MS method for identifying CSF amyloid positivity in mild cognitive impairment. Frontiers in Aging Neuroscience. 17. 1681516–1681516.
2.
Allué, José Antonio, María Pascual‐Lucas, Leticia Sarasa, et al.. (2023). Clinical utility of an antibody‐free LC‐MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 15(2). e12451–e12451. 5 indexed citations
3.
Chun, Min Young, Hyemin Jang, Hee Jin Kim, et al.. (2023). Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity. Frontiers in Aging Neuroscience. 15. 1126799–1126799. 4 indexed citations
4.
Pascual‐Lucas, María, Leticia Sarasa, Sergio Castillo, et al.. (2023). AB1601 Phase 2 Study of ABvac40, an Anti‐Aβ40 Vaccine: Safety and Immunogenicity of a Cross‐Over Extension. Alzheimer s & Dementia. 19(S24). 2 indexed citations
5.
Castillo, Sergio, Noelia Fandos, Judith Romero, et al.. (2022). AB1601 topline results – Phase 2 study of ABvac40 in patients with amnestic mild cognitive impairment (a‐MCI) or very mild Alzheimer’s Disease (Vm‐AD).. Alzheimer s & Dementia. 18(S10). 2 indexed citations
6.
Jang, Hyemin, Duk L. Na, Hee Jin Kim, et al.. (2021). Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort. Alzheimer s Research & Therapy. 13(1). 179–179. 19 indexed citations
7.
Janelidze, Shorena, Sebastian Palmqvist, Antoine Leuzy, et al.. (2021). Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer s & Dementia. 17(S5). 5 indexed citations
8.
Janelidze, Shorena, Charlotte E. Teunissen, Henrik Zetterberg, et al.. (2021). Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurology. 78(11). 1375–1375. 267 indexed citations breakdown →
9.
Pascual‐Lucas, María, et al.. (2021). Aβ42/Aβ40 ratio in plasma predicts amyloid‐PET status in amnestic‐MCI patients. Alzheimer s & Dementia. 17(S5). 1 indexed citations
10.
Cullen, Nicholas, Antoine Leuzy, Sebastian Palmqvist, et al.. (2020). Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging. 1(1). 114–123. 119 indexed citations
11.
Pérez‐Grijalba, Virginia, Javier Arbizu, Judith Romero, et al.. (2019). Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alzheimer s Research & Therapy. 11(1). 96–96. 39 indexed citations
12.
Pérez‐Grijalba, Virginia, Judith Romero, Pedro Pesini, et al.. (2019). Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study. The Journal of Prevention of Alzheimer s Disease. 6(1). 34–41. 76 indexed citations
13.
Pascual‐Lucas, María, Pedro Pesini, Virginia Pérez‐Grijalba, et al.. (2018). Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimer s Research & Therapy. 10(1). 12–12. 81 indexed citations
14.
Allué, José Antonio, Leticia Sarasa, María Izco, et al.. (2016). Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer’s Disease. Journal of Alzheimer s Disease. 53(3). 773–785. 10 indexed citations
15.
Pérez‐Grijalba, Virginia, Pedro Pesini, José Antonio Allué, et al.. (2014). Aβ1-17 is a Major Amyloid-β Fragment Isoform in Cerebrospinal Fluid and Blood with Possible Diagnostic Value in Alzheimer's Disease. Journal of Alzheimer s Disease. 43(1). 47–56. 12 indexed citations
16.
Sarasa, Leticia, Ángela González‐Martínez, M. Suárez, et al.. (2014). Neprilysin Is Poorly Expressed in the Prefrontal Cortex of Aged Dogs with Cognitive Dysfunction Syndrome. International Journal of Alzheimer s Disease. 2014. 1–7. 8 indexed citations
17.
Sarasa, Leticia, José Antonio Allué, Pedro Pesini, Ángela González‐Martínez, & Manuel Sarasa. (2013). Identification of β-amyloid species in canine cerebrospinal fluid by mass spectrometry. Neurobiology of Aging. 34(9). 2125–2132. 9 indexed citations
18.
Sarasa, Leticia, et al.. (2013). Prevention of Amyloid-β Fibril Formation Using Antibodies Against the C-terminal Region of Amyloid-β1-40 and Amyloid-β1-42. Journal of Alzheimer s Disease. 34(1). 133–137. 6 indexed citations
19.
Sarasa, Leticia, José Antonio Allué, Inmaculada Monleón, et al.. (2012). O2‐03‐05: Beta‐amyloid‐17 is a major beta‐amyloid fragment isoform in cerebrospinal fluid and blood that shows diagnostic value. Alzheimer s & Dementia. 8(4S_Part_7). 6 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wagner S. Brum Breakdown of academic impact, for papers by Josef Pannee Breakdown of academic impact, for papers by Jeroen Vanbrabant Breakdown of academic impact, for papers by Virginia Pérez‐Grijalba Breakdown of academic impact, for papers by Marwan Sabbagh Breakdown of academic impact, for papers by Federica Ribaldi Breakdown of academic impact, for papers by Manu Vandijck Breakdown of academic impact, for papers by Joakim Hertze Breakdown of academic impact, for papers by Francesco Garaci Breakdown of academic impact, for papers by Luiza Spiru
Rankless by CCL
2026